A non-hallucinogenic version of the psychedelic drug ibogaine has been developed by David Olson and colleagues at the UC Davis Department of Chemistry. The new compound shows potential for treating psychiatric disorders including addiction in animal models and may work by increasing connectivity between nerve cells. Image of nerve cells by Lindsay Cameron, UC Davis
A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis.
A paper describing the work is published Dec. 9 in Nature.
“Psychedelics are some of the most powerful drugs we know of that affect the brain,” said David Olson, assistant professor of chemistry at UC Davis and senior author on the paper. “It’s unbelievable how little we know about them.”
Ibogaine is extracted from the plant Tabernanthe iboga. There are anecdotal reports that it can have powerful anti-addiction effects such as reducing drug cravings and preventing relapse. But there are also serious side-effects, including hallucinations and cardiac toxicity, and the drug is a Schedule 1 controlled substance under U.S. law.
Olson’s laboratory at UC Davis is one of a few in the U.S. licensed to work with Schedule 1 substances. They set out to create a synthetic analog of ibogaine which retained therapeutic properties without the undesired effects of the psychedelic compound. Olson’s team worked through a series of similar compounds by swapping out parts of the ibogaine molecule. They engineered a new, synthetic molecule which they named tabernanthalog or TBG.
Models of anxiety, depression and addiction
Unlike ibogaine, the new molecule is water-soluble and can be synthesized in a single step. Experiments with cell cultures and zebrafish show that it is less toxic than ibogaine, which can cause heart attacks and has been responsible for several deaths.
TBG increased formation of new dendrites (branches) in rat nerve cells, and of new spines on those dendrites. That’s similar to the effect of drugs like ketamine, LSD, MDMA and DMT (the active component in the plant extract ayahuasca) on connections between nerve cells.
TBG did not, however, cause a head twitch response in mice, which is known to correlate with hallucinations in humans.
A series of experiments in rodent models of depression and addiction show that the new drug has promising positive effects. These animal models – conducted in accordance with NIH regulations and reviewed and approved by Institutional Animal Care and Use Committees – remain vital to investigating complex psychiatric disorders.
Mice trained to drink alcohol cut back their consumption after a single dose of TBG. Rats were trained to associate a light and tone with pressing a lever to get a dose of heroin. When the opiate is taken away, the rats develop signs of withdrawal and press the lever again when given the light and sound cues. Treating the rats with TBG had a long-lasting effect on opiate relapse.
Olson thinks that TBG works by changing the structure of neurons in key brain circuits involved in depression, anxiety, post-traumatic stress disorder and addiction.
“We’ve been focused on treating one psychiatric disease at a time, but we know that these illnesses overlap,” Olson said. “It might be possible to treat multiple diseases with the same drug.”
Indeed, psychedelic therapies have been attracting new interest in recent years. But taking patients on individual ‘trips’ is time consuming and costly, requiring hours of close medical supervision apart from the possible negative effects.
“We need a drug that people can keep in their medicine cabinet and this is a significant step in that direction,” Olson said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Tabernanthalog
- Feed has no items.
Go deeper with Google Headlines on:
Tabernanthalog
[google_news title=”” keyword=”tabernanthalog” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Psychedelic therapies
- Vermont bill to study psychedelic therapy heads to governor's desk
He described being "really happy the state of Vermont is interested in getting a group together to consider how we can be a leader among states" looking into psychedelic therapies. His hope is to have ...
- UCLA Health symposium explores the fusion of psychedelic therapies and ecological medicine
UCLA Health is set to host a unique symposium this week to explore the evolving research in psychedelic therapies and how combining it with reconnection to natural world could help to amplify their ...
- Psychedelic therapy: FDA panel to review first ever MDMA-assisted PTSD treatment
A committee of independent advisers to the Food and Drug Administration will meet on June 4 to review data supporting the new drug application for the first ever MDMA-assisted therapy for adults with ...
- Welcome to the Age of Psychedelic Inequality
Psychedelic-assisted therapies have been hailed as the wave of the future. They’re also becoming big business. What if most people can’t afford them?
- Dr. Richard Goldberg Joins Real Brands' Board of Directors, Enters Consulting Agreement
Dr. Richard J. Goldberg has joined Real Brands Inc.'s Board of Directors and will consult for them on research and development of psychedelic drug therapies. "Dr. Goldberg is a renowned, award-winning ...
Go deeper with Google Headlines on:
Psychedelic therapies
[google_news title=”” keyword=”psychedelic therapies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]